Protein-functionalized and intrinsically radiolabeled [188Re]ReOx nanoparticles: advancing cancer therapy through concurrent radio-photothermal effects

• DOI: 10.1007/s00259-025-07074-9
• Publication Date: 2025-01-25T02:53:21Z
• Authors: Sanchita Ghosh; Apurav Guleria; Sourav Patra; Avik Chakraborty; Kanhu Charan Barick; Chandan Kumar; Khajan Singh; Sutapa Rakshit; Rubel Chakravarty
• Keywords: Cancer Therapy

Enhancing therapeutic effectiveness is crucial for translating anticancer nanomedicines from laboratory to clinical settings. In this study, we have developed radioactive rhenium oxide nanoparticles encapsulated in human serum albumin ([188Re]ReOx-HSA NPs) concurrent radiotherapy (RT) and photothermal therapy (PTT), aiming optimize treatment outcomes. [188Re]ReOx-HSA NPs were synthesized by a controlled reduction of 188ReO4− HSA medium extensively characterized. The effect was demonstrated vitro murine melanoma (B16F10) cell line. vivo SPECT/CT imaging, autoradiography biodistribution studies performed after intratumoral injection tumor-bearing C57BL/6 mice. potential combined RT PTT also the aforesaid mice model. (size 4–6 nm) with high colloidal radiochemical stability. Upon laser (808 exposure on B16F10 cells incubated NPs, only < 20% alive demonstrating efficacy under Uniform dose distribution retention radiolabeled tumor volume observed via imaging studies. Tumor growth model significantly arrested ~ 1.85 MBq simultaneous irradiation, synergistic benefit PTT. These results demonstrate that intrinsically having unique features such as effects favorable nuclear decay characteristics RT/PTT, hold great promise translation.